Related Experiment Video
Updated: Oct 17, 2025

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
Published on: September 9, 2011
Romosozumab and cardiovascular safety in Japan
1Toranomon Hospital Endocrine Center, Tokyo, Japan.
Abstract:
Romosozumab is a potent pharmacological tool to prevent fractures in osteoporosis patients, and its mechanism of action is distinct from any other drugs. The efficacy of romosozumab to prevent osteoporotic fractures is remarkable. However, there remains a concern of increased cardiovascular adverse events. Further relevant investigations are essential to understand whether romosozumab is actually involved in the development of cardiovascular events or not. We need more robust evidence to establish an appropriate and reasonable guide to prescribe romosozumab in our clinical practice.
More Related Videos
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Coronary Artery Disease IV: Preventive Measures
Rheumatic Heart Disease I: Introduction
Cardiovascular Drugs: Classification based on Therapeutic Indications
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

